BioSpace News Archive

Company continues to prepare its lead product candidate, PRP, for a Phase IB, First-In-Human study, in advanced cancer patients suffering from solid tumors

Aegea Biotechnologies, Inc. (“Aegea”) ( www.aegeabiotech.com ), a biotechnology company focused on the development and commercialization of next generation nucleic-acid diagnostic technologies, announces progress on the development of its Point-of-Care (“POC”) COVID-19 diagnostic test.

RNA and DNA extraction plays a crucial role in cancer genetic studies, which involves mutation analysis, comparative genomic hybridization, and microsatellite analysis.

According to the latest report published by Transparency Market Research on the global personal mobility devices market for the historical period of 2013 - 2017 and forecast period of 2019 to 2027, increase in the geriatric population and large population suffering from physical disabilities are projected to boost the growth of the global personal mobility devices market during the forecast period

Treatment Options Targeting Brain’s Thermostat Lead to Innovations in Non-hormonal Drugs

The demand within the global infusion therapy devices market has been increasing on account of advancements in medical processes and procedures.

Opthea Limited is pleased to announce that it will host a Key Opinion Leader symposium focused on OPT-302, the Company’s first-in-class biologic inhibitor of VEGF-C/D, in development for the treatment of wet age-related macular degeneration and diabetic macular edema.

Swedish Orphan Biovitrum AB announced that the strategic licensing agreement with Selecta Biosciences, Inc. for SEL-212, entered into as earlier announced on June 11, 2020, became effective on July 28, 2020, following the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period.

RadNet, Inc. announced that it will host a conference call to discuss its second quarter 2020 financial results on Monday, August 10th, 2020 at 7:30 a.m.

CytoSorbents Corporation, CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q2 2020 financial results after the market close on Tuesday, August 4, 2020.